194669-46-0

Upstream product

• 871112-35-5 tert-butyl 4-hydroxy-4-(3-methoxyphenyl)piperidine-1-carboxylate 
• 194669-45-9 4-(3-methoxy-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 36282-40-3 (3-methoxyphenyl)magnesium bromide 
• 10365-98-7 3-methoxyphenylboronic acid 

Downstream Products

• 437998-48-6 2-{4-[4-(3-methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-butyrylamino}-benzamide 
• 725739-55-9 4-(3-methoxy-phenyl)-3,6-dihydro-2H-pyridine-1-sulfonyl chloride 
• 1010073-04-7 C₂₅H₃₄N₂O₄ 
• 107335-36-4 N-methyl-2-{2-[2-(4-(3-methoxyphenyl)-1,2,3,6-tetrahydropyridin-1-yl)ethyloxy]phenyl}thiazolidine-3-carbothioamide 
• 107335-66-0 2-(2-{2-[4-(3-Methoxy-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-ethoxy}-phenyl)-thiazolidine-3-carboxylic acid methylamide 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists

Aryl-tetrahydropyridine derivatives were prepared and their PPARα/γ dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPARα/γ dual agonist with an EC50 of 1.73 and 0.64 μM in hPPARα and γ, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties.

Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugs

A novel series of TNF inhibitors was identified based on the screening of existing MMP inhibitor libraries. Further SAR optimization led to the discovery of a novel lead compound. Its synthesis, efficacy in experimental animal models, and pharmacokinetic